Stay updated on Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page now shows a 403 Forbidden error indicating restricted access to the study record. Additionally, sponsor-related content and study documents associated with Merck were removed from the page.SummaryDifference22%

- Check38 days agoChange DetectedThe page now includes a 2015 NIH grant/contract annotation and updates the release version from v3.6.5 to v3.6.6.SummaryDifference0.1%

- Check60 days agoChange DetectedA new revision tag 'Revision: v3.6.5' has been added, and the 'Plain Language Summary' section along with the previous 'Revision: v3.6.4' has been removed, indicating an update to the page's content and presentation.SummaryDifference0.1%

- Check74 days agoChange DetectedThe footer displays Revision: v3.6.4, replacing Revision: v3.6.3. This indicates a minor site revision without changes to the study details.SummaryDifference0.0%

- Check96 days agoChange DetectedRevision label in the page footer updated from v3.6.2 to v3.6.3, indicating a new version of the page/component.SummaryDifference0.0%

- Check103 days agoChange DetectedThe page shows Revision: v3.6.2 now replaces the previous Revision: v3.6.0 in the footer metadata. This reflects a small site maintenance update that does not alter the study information.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic Lung Cancer Clinical Trial page.